Spots Global Cancer Trial Database for squamous
Every month we try and update this database with for squamous cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. | NCT03968419 | Non-small Cell ... | Canakinumab Pembrolizumab | 18 Years - | Novartis | |
| Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers | NCT03515538 | Oral Mucositis | RRx-001 Cisplatin for i... Radiation Thera... | 18 Years - | EpicentRx, Inc. | |
| A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | NCT03430843 | Esophageal Squa... | Tislelizumab Paclitaxel Docetaxel Irinotecan | 18 Years - | BeiGene | |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers | NCT02583542 | Triple-Negative... Squamous Cell L... Non-squamous Ce... Non-squamous Ce... | AZD2014 AZD6244 | 18 Years - | Queen Mary University of London | |
| Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer | NCT01577654 | Non Small Cell ... | EC145 EC145 + Docetax... Docetaxel EC20 | 18 Years - | Endocyte | |
| Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer | NCT02250326 | Carcinoma, Non-... | nab-paclitaxel ... CC-486 Duravalumab | 18 Years - | Celgene | |
| Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers | NCT02423590 | Squamous Cell L... | Apatorsen (OGX-... Gemcitabine Carboplatin | 18 Years - | Queen Mary University of London | |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | NCT02403271 | Non-Small Cell ... Breast Cancer Pancreatic Canc... | Ibrutinib Durvalumab | 18 Years - | Pharmacyclics LLC. | |
| A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | NCT03430843 | Esophageal Squa... | Tislelizumab Paclitaxel Docetaxel Irinotecan | 18 Years - | BeiGene | |
| Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers | NCT02423590 | Squamous Cell L... | Apatorsen (OGX-... Gemcitabine Carboplatin | 18 Years - | Queen Mary University of London | |
| PET-CT for Squamous Cell Carcinoma (SCC) of the Neck Nodes Unknown Primary Malignancy | NCT00530283 | Squamous Cell C... | PET-CT | 18 Years - | AHS Cancer Control Alberta | |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers | NCT02583542 | Triple-Negative... Squamous Cell L... Non-squamous Ce... Non-squamous Ce... | AZD2014 AZD6244 | 18 Years - | Queen Mary University of London | |
| Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer | NCT01577654 | Non Small Cell ... | EC145 EC145 + Docetax... Docetaxel EC20 | 18 Years - | Endocyte | |
| Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers | NCT03515538 | Oral Mucositis | RRx-001 Cisplatin for i... Radiation Thera... | 18 Years - | EpicentRx, Inc. | |
| Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers | NCT03515538 | Oral Mucositis | RRx-001 Cisplatin for i... Radiation Thera... | 18 Years - | EpicentRx, Inc. | |
| Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma | NCT00596219 | SQUAMOUS CELL C... | celecoxib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients. | NCT00315159 | Vulvar Cancer | Sentinel Node B... | 18 Years - | Women and Infants Hospital of Rhode Island | |
| Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers | NCT05910827 | Advanced or Met... | HMBD-001 Docetaxel Cetuximab | 18 Years - | Hummingbird Bioscience | |
| Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer | NCT04205812 | Metastatic Squa... Metastatic Nons... | Retifanlimab Placebo Pemetrexed Cisplatin Carboplatin Paclitaxel nab-Paclitaxel | 18 Years - | Incyte Corporation | |
| Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer | NCT02924233 | Squamous Non-Sm... | Sym004 Nivolumab | 18 Years - | Symphogen A/S | |
| Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer | NCT04205812 | Metastatic Squa... Metastatic Nons... | Retifanlimab Placebo Pemetrexed Cisplatin Carboplatin Paclitaxel nab-Paclitaxel | 18 Years - | Incyte Corporation | |
| PET-CT for Squamous Cell Carcinoma (SCC) of the Neck Nodes Unknown Primary Malignancy | NCT00530283 | Squamous Cell C... | PET-CT | 18 Years - | AHS Cancer Control Alberta | |
| Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. | NCT05791097 | Non-small Cell ... | Ociperlimab Placebo Tislelizumab Pembrolizumab Carboplatin Cisplatin Pemetrexed Paclitaxel Nab-paclitaxel | 18 Years - | Novartis | |
| First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin | NCT00981058 | Non Small Cell ... | Necitumumab Gemcitabine Cisplatin | 18 Years - | Eli Lilly and Company | |
| Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% | NCT04139317 | Non-small Cell ... | Capmatinib Pembrolizumab | 18 Years - | Novartis | |
| Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer | NCT00509366 | Non Small Cell ... | Cisplatin & Gem... Cisplatin & Pem... Docetaxel & Gem... Pemetrexed & Ge... | 18 Years - | Duke University | |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | NCT05199584 | Solid Tumors Wi... | ENV-101 (talade... | 18 Years - | Endeavor Biomedicines, Inc. | |
| Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects | NCT03631199 | Non-small Cell ... | canakinumab canakinumab mat... pembrolizumab carboplatin cisplatin paclitaxel nab-paclitaxel pemetrexed | 18 Years - | Novartis | |
| Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | NCT04794699 | Solid Tumor | IDE397 Docetaxel Paclitaxel Sacituzumab gov... | 18 Years - | IDEAYA Biosciences | |
| Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients. | NCT00315159 | Vulvar Cancer | Sentinel Node B... | 18 Years - | Women and Infants Hospital of Rhode Island | |
| Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma | NCT01764607 | Squamous Cell S... | Sirolimus | 18 Years - | University of Florida | |
| Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis | NCT02817958 | Penile Cancer Squamous Carcin... | Chemotherapy TI... | 18 Years - | UNICANCER | |
| Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. | NCT05791097 | Non-small Cell ... | Ociperlimab Placebo Tislelizumab Pembrolizumab Carboplatin Cisplatin Pemetrexed Paclitaxel Nab-paclitaxel | 18 Years - | Novartis | |
| First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin | NCT00981058 | Non Small Cell ... | Necitumumab Gemcitabine Cisplatin | 18 Years - | Eli Lilly and Company | |
| A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT01160744 | Carcinoma, Non-... | IMC-1121B (ramu... Pemetrexed Carboplatin (AU... Cisplatin Gemcitabine Carboplatin (AU... | 18 Years - | Eli Lilly and Company | |
| Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer | NCT02924233 | Squamous Non-Sm... | Sym004 Nivolumab | 18 Years - | Symphogen A/S | |
| Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% | NCT04139317 | Non-small Cell ... | Capmatinib Pembrolizumab | 18 Years - | Novartis | |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | NCT04596033 | Melanoma Non-small Cell ... Squamous Cell C... Urothelial Carc... Renal Cell Carc... Small-cell Lung... Cutaneous Squam... Anal Squamous C... Merkel Cell Car... | GEN-011 IL-2 Fludarabine Cyclophosphamid... | 18 Years - | Genocea Biosciences, Inc. | |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | NCT02403271 | Non-Small Cell ... Breast Cancer Pancreatic Canc... | Ibrutinib Durvalumab | 18 Years - | Pharmacyclics LLC. | |
| A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT01160744 | Carcinoma, Non-... | IMC-1121B (ramu... Pemetrexed Carboplatin (AU... Cisplatin Gemcitabine Carboplatin (AU... | 18 Years - | Eli Lilly and Company | |
| A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer | NCT05275673 | Non-Small Cell ... Squamous Non-sm... Squamous Non-Sm... NFE2L2 Gene Mut... | sapanisertib | 18 Years - | Calithera Biosciences, Inc | |
| Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis | NCT02817958 | Penile Cancer Squamous Carcin... | Chemotherapy TI... | 18 Years - | UNICANCER |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
